📰 Transcode Therapeutics News
Transcode Therapeutics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Transcode Therapeutics. Real-time updates on events, politics, business and more.
May 23, 2024
Using RNA Therapeutics to Deliver a Cancer-Free Future NASDAQ: RNAZ April 12, 2024 ...
May 20, 2024
HC Wainwright reaffirmed their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock. TransCode Therapeutics Stock Performance RNAZ stock opened at $1.15 on Thursday. The stock’s 50 day moving average price is […]
May 16, 2024
Cogent Biosciences (NASDAQ:COGT – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Analyst Ratings This is a breakdown of […]
April 29, 2024
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 18,600 shares, a decline of 53.5% from the March 31st total of 40,000 shares. Based on an average daily volume of 588,800 shares, […]
April 19, 2024
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. TransCode Therapeutics Stock Performance RNAZ stock opened at $0.50 on Tuesday. TransCode Therapeutics has a 52 week low of $0.47 and a 52 […]
April 10, 2024
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – HC Wainwright upped their FY2024 EPS estimates for TransCode Therapeutics in a research report issued on Wednesday, April 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($2.14) per share for the year, up from their prior estimate of ($25.20). HC […]
April 3, 2024
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. TransCode Therapeutics Stock Performance Shares of RNAZ traded down $0.01 during trading hours on Wednesday, reaching $0.67. 138,372 shares of the company traded hands, compared to its […]